MedicineOncologyPathologyGenitourinary OncologyMolecular OncologyProstate DiseaseMalignant NeoplasmsProstate BiopsyProstate CancerProstate PathologyProstatic PathologyTumor AntigensGleason ScoringProstate Cancer PrognosisProstate HistologyProstate Tumor MarkersTransurethral Resection Specimen Evaluation
Cancer cell proliferation could be an important predictor of clinical behavior and survival in node-negative prostate cancers. Proliferating cell nuclear antigen (PCNA; PC10) immunostaining was determined in 38 prostate biopsies and transurethral resections in clinically organ confined prostate cancers. 14 of the prostate cancers were Gleason score 2-4 and 24 were Gleason score 5-7. 29 were stage T2 and 9 were stage T3. Gleason score 2-4 cancers had a mean PCNA of 7.08 (s.d 5.1); Gleason score 5-7 had a mean PCNA of 11.42 (s.d 7.7), Stage T2 cancers had a mean PCNA of 8.007 (s.d 6.13) and stage T3 cancers had a mean PCNA of 12.7 (s.d 8.49). 21.4% of Gleason score 2-4, 12.5% of Gleason score 5-7, 10.7% of stage T2 and 10% of stage T3 had mean PCNA counts of twice their mean values. 4/24 (16.67%) of Gleason score 5-7 and 28.57% of stage T3 cancers had total PCNA counts > 20/2hpf suggesting high counts are indices of progression.